Back to Authors

Wang, Y.

A5068607002 | I1330342723

Mayo Clinic

Citations 9

122 | IDENTIFYING HARMFUL HYPERINFLAMMATION IN DIFFUSE LARGE B‐CELL LYMPHOMA USING THE OHI (OPTIMIZED HLH INFLAMMATORY) INDEX—DISCOVERY AND VALIDATION IN REAL‐WORLD PATIENTS

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_122

271 | LEUKEMIC NON‐NODAL MANTLE CELL LYMPHOMA IS NOT NECESSARILY EQUIVALENT TO INDOLENT MCL: A REPORT FROM THE LEO COHORT STUDY

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_271

307 | IMPACT OF CELL OF ORIGIN, GENE REARRANGEMENTS, FRONTLINE TREATMENT ON INCIDENCE OF CENTRAL NERVOUS SYSTEM LYMPHOMA RELAPSE IN NEWLY DIAGNOSED LARGE B‐CELL LYMPHOMA

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_307

29 | A COMPARATIVE ANALYSIS OF HISTOLOGIC TRANSFORMATION OF FOLLICULAR LYMPHOMA AT DIAGNOSIS (COMPOSITE LYMPHOMA) AND SEQUENTIALLY TRANSFORMED FOLLICULAR LYMPHOMA

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_29

289 | MULTICENTER REAL‐WORLD OUTCOMES OF FRONTLINE POLA‐R‐CHP IN TREATMENT NAÏVE DLBCL

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_289

324 | RAPID RAMP‐UP DOSING OF BI‐SPECIFIC ANTIBODIES IN RELAPSED OR REFRACTORY LARGE B‐CELL LYMPHOMA

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70094_324

Depth of metabolic response at interim PET and survival outcomes among patients with primary refractory or early relapsing diffuse large B‐cell lymphoma (DLBCL)

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 344-345

10.1002/hon.3164_246

Automated FDG PET/CT radiomics for risk stratification in newly diagnosed diffuse large B‐cell lymphoma (DLBCL)

Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 341-342

10.1002/hon.3164_244

INTERIM PET/CT PREDICTS OUTCOMES OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) TREATED WITH FRONTLINE LENALIDOMIDE/RCHOP (R2CHOP): LONG‐TERM ANALYSIS OF MC078E

Hematological Oncology | June 17, 2021 | Volume: 39 | Issue: S2 | Pages: No page available

10.1002/hon.83_2880